Abstract. The causes of lung cancer in never-smokers remain unclear. The potential contribution of human papillomavirus (HPV) to the carcinogenesis of non-small cell lung cancer (NSCLC) has been reported. In 2008, a prospective registry of never-smokers with NSCLC was established at the Kinki-Chuo Chest Medical Center, Sakai, Osaka, Japan. Never-smokers with NSCLC were consecutively enrolled onto the registry. Of these patients, 114 with large tumor specimens, the majority of which were surgical tissues, were selected. In total, 23 of the most clinically relevant HPV types were assayed using polymerase chain reaction amplification of the viral genome. Following exclusion of samples with suboptimal quality, DNA was extracted from 96 formalin-fixed paraffin-embedded samples. These 96 cases consisted of 82 females (85.4%) and 14 males (14.6%), with a median age of 67 years (range, 29-83). Almost all cases (93.8%) were of the adenocarcinoma histological subtype. Despite confirmation of the quality and amount of DNA, HPV type 6 was detected in only one case (1.1%). Furthermore, no other samples examined were positive for any other HPV types. The results therefore suggest that HPV does not play a major role as the driving oncogenic event in never-smokers with NSCLC.

Introduction

While lung cancer is the leading cause of cancer-related mortality and is predominantly caused by tobacco smoke, ~25% of all lung cancers worldwide are not attributable to tobacco smoke (1). In fact, in a large Japanese cohort study of >20,000 patients with non-small cell lung cancer (NSCLC), 30% were never-smokers (2). Lung cancer in never-smokers is unique with regard to its clinical characteristics and is suggested to be a distinct disease, which has emerged as a global public health concern (3,4). Investigations into the molecular mechanisms responsible for the disease are urgently necessary in order to improve therapeutic strategies. A number of etiological factors have been proposed, with infection with oncogenic human papillomavirus (HPV) as one of these (5-7). A recent study on the comprehensive genome sequencing of cancer revealed that the apobec3b protein was associated with carcinogenesis in multiple cancers, including lung cancer (8). Viral infection is known to play a significant role in upregulating proteins. In fact, cervical cancer and pharyngo-laryngeal cancer have been classified into a unique mutational signature that is associated with HPV (8).a

A meta-analysis previously demonstrated that the prevalence of HPV in lung cancer is highly variable around the world, with higher HPV frequencies observed in East Asian countries compared with European countries (9). However, inadequate sample collection or handling errors leading to contamination may contribute to these variations (10). At the Kinki-Chuo Chest Medical Center (Sakai, Osaka, Japan) only patients with lung diseases are treated, which is an advantage in the avoidance of clinical sample contamination. In the present study, a prospective registry investigation into the involvement of HPV in NSCLC in never-smokers at the Kinki-Chuo Chest Medical Center is reported.

Patients and methods

Tissue specimens from prospective registry of never-smokers. In 2008, a prospective registry of never-smokers with NSCLC was established at the National Hospital Organization Kinki-Chuo Chest Medical Center. Subsequent to obtaining written informed consent, patients were enrolled prospectively and consecutively to determine if they had newly diagnosed or histologically or cytologically confirmed NSCLC. The patients were never-smokers (<100 cigarettes/lifetime) and
had tumor tissue samples available for analysis. All patients were requested to complete a detailed questionnaire, including confirmation of never-smoker status and any family history of cancer and passive smoking status (11). A total of 250 patients were enrolled between March 2008 and January 2010, and clinical data was collected from medical records and questionnaires. Among the 250 patients, 114 with sufficiently large tumor specimens were selected, the majority of which were surgical tissues.

This study was approved by the Institutional Review Board of the National Hospital Organization Kinki-Chuo Chest Medical Center.

**HPV DNA genotyping.** HPV genotyping was performed using a polymerase chain reaction (PCR)-based microarray system (GeneSQUARE, Kurabo, Osaka, Japan) to detect 23 HPV types, including high-risk (HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68), low-risk or risk-unknown types (HPV types 6, 11, 30, 34, 39, 40, 42, 53, 54, 61 and 66). This system uses type-specific primers and probes that are designed to detect the E2, E6, E7, L1 and L2 genes. The target HPV-DNA was amplified by PCR using a Mastercycler gradient (Eppendorf, Hambrug, Germany). PCR was performed in a total volume of 20 µl, containing multiple primers for each of the HPV types (GenBank accession numbers: AF092932, M14119, NC_001526, X05015, X74474, J04353, M12732, X74476, M74117, M62849, X74478, M73236, X74479, M62877, X74481, X74482, U37488, X74483, D90400, X77858, U31793, U31794, M73258 and 123996136 for HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68, respectively) FastStart Taq DNA polymerase (Roche Diagnostics, Basel, Switzerland), dNTP mix, dUTP labeled with Cy3 and specimen DNA. A total of 100-1,000 ng/3 µl specimen DNA was used in each reaction. PCR conditions were as follows: 4 min at 95°C, followed by 40 cycles of 95°C for 30 sec, 65°C for 30 sec, 72°C for 1 min, and one cycle of 72°C for 7 min. The DNA samples were then applied to HPV genotyping arrays and hybridization was performed at 65°C for 1 h. Samples were washed and dried, and analysis was performed using a micro-array scanner (12). The HPV positivity rate was calculated based on positive results by either consensus PCR or genotyping, both of which use different primer settings. Molecular analysis was performed at least twice for confirmation.

**Results**

**Clinical characteristics.** Following the exclusion of the samples with suboptimal quality from the 114 patients, DNA was successfully extracted from 96 formalin-fixed paraffin-embedded surgical tissues. The clinical characteristics of these 96 cases are summarized in Table I. The cases consisted of 82 female patients (85.4%) and 14 male patients (14.6%), with a median age of 67 years (range, 29-83 years). The majority of the cases exhibited adenocarcinoma histology (93 patients: 93.8%). Molecular biological analysis of the 93 patients with adenocarcinoma showed 59 epidermal growth
factor (EGFR) mutations (63.4%), five KRAS mutations (5.4%) and four EML4-ALK rearrangements (4.3%).

**HPV detection.** HPV type 6 was detected in only one case (1.0%) among the 96 tumor samples. The patient was a 49-year-old female who presented with an EGFR mutation (exon 19) with wild-type KRAS and ALK. The patient had previously undergone surgery twice for condyoma acuminatum, and had stage I adenocarcinoma. During a 25-year period, the patient was subjected to environmental tobacco smoke exposure (from 28 to 53 years of age at home, and from 58 to 59 years at work). At five years post-surgery, the patient experienced a recurrence of the lung cancer. Following treatment with gefitinib (250 mg/day) for one year, the patient succumbed to brain metastasis subsequent to several rounds of chemotherapy.

No other patients examined were positive for any HPV types, including high-risk (HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68), low-risk or risk-unknown types (HPV types 6, 11, 30, 34, 40, 42, 53, 54, 61 and 66).

**Discussion**

In the present study, a low-risk HPV type was evident in one case among 96. However, no HPV of any type was detected in any other tumors. These results suggest that HPV does not play a major role as the driving oncogenic event in lung cancer in never-smokers in Osaka, Japan.

It is known that HPV types essentially cause all human cervical cancers (13). During the last two decades, several studies have examined the possible involvement of HPV in non-genital cancers and have proposed the presence of HPV in esophageal, laryngeal, oropharyngeal, urothelial, breast, colon and lung cancer (14). The virus is able to infect the oral mucosa, the larynx and the bronchial tissues, which therefore may be the primary source of HPV detected in the lung (15). In fact, Carpagnano et al demonstrated the presence of HPV in the exhaled breath condensate of lung cancer patients (16).

Although the data from the present study suggest that HPV involvement in lung cancer is unlikely in never-smokers, the issue remains controversial. According to previous studies, the prevalence of HPV is not uniform (9,17). Regional differences exist within Asia, the Americas, Europe and throughout Japan. Higher levels are observed in Okinawa and southern areas of Japan compared with Tokyo and central areas (9).

There are several advantages to the present study. Firstly, the data in this study is accurate, as it was obtained by detailed questionnaires and interviews of the patients and their families. Secondly, the HPV genotyping used a high precision test and included a range of 23 HPV types, including low- and high-risk types. In order to further clarify HPV carcinogenesis, a nationwide prospective study of the viral molecular epidemiology of Japan is required. This should consider the association between viral infection and carcinogenesis, and regional differences in HPV prevalence (7).

In conclusion, a low-risk HPV type was evident in one patient sample, and no other lung cancer tumors that were examined were positive for any HPV types in the never-smokers. These results suggest that HPV does not play a major role as the driving oncogenic event in never-smokers in Osaka, central Japan.

**Acknowledgements**

The authors would like to thank Dr Yoshikazu Hasegawa of Izumi City Hospital for the critical review and Ms. Risa Sakaguchi for providing secretarial assistance. This study was supported in part by a Grant-in-Aid for Cancer Research from the Osaka Medical Research Foundation for Intractable Disease.

**References**

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Kawaguchi T, Takada M, Kubo A, et al: Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol 5: 620-630, 2010.
3. Sun S, Schiller JH and Gazdar AF: Lung cancer in never-smokers - a different disease. Nat Rev Cancer 7: 778-790, 2007.
4. Subramanian J and Govindan R: Molecular genetics of lung cancer in people who have never smoked. Lancet Oncol 9: 676-682, 2008.
5. Li X, Sheu CC, Ye Y, et al: Genetic variants and risk of lung cancer in never-smokers: a genome-wide association study. Lancet Oncol 11: 321-330, 2010.
6. Raso MG, Behrens C, Herynk MH, et al: Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res 15: 5359-5368, 2009.
7. Kawaguchi T, Ando M, Ito N, et al: Rationale and design of the Japan molecular epidemiology for lung cancer study. Clin Lung Cancer 14: 596-600, 2013.
8. Kuong KJ and Loeb LA: APOBEC3B mutagenesis in cancer. Nat Genet 45: 964-965, 2013.
9. Hasegawa Y, Ando M, Kubo A, et al: Human papilloma virus in non-small cell lung cancer in never-smokers: A systematic review of the literature. Lung Cancer 83: 8-13, 2014.
10. Koshidjio J, Rotunno M, Gillison ML, et al: Assessment of human papillomavirus in lung tumor tissue. J Natl Cancer Inst 105: 501-507, 2011.
11. Kawaguchi T, Ando M, Kubo A, et al: Long exposure of environmental tobacco smoke associated with activating EGFR mutations in never-smokers with non-small cell lung cancer. Clin Cancer Res 17: 39-45, 2011.
12. Ermel A, Qadadri B, Morishita A, et al: Human papillomavirus detection and typing in thin prep cervical cytologic specimens comparing the Digene Hybrid Capture II Assay, the Roche Linear Array HPV Genotyping Assay, and the Kurabo GeneSquare Microarray Assay J Virol Methods 169: 154-161, 2010.
13. Schiffman M and Solomon D: Clinical practice. Cervical-cancer screening with human papillomavirus and cytologic cotesting. N Engl J Med 362: 2324-2331, 2013.
14. Mammas IN, Sourvinos G, Zaravinos A and Spandidos DA: Vaccination against human papilloma virus (HPV): epidemiological evidence of HPV in non-genital cancers. Pathol Oncol Res 17: 103-119, 2011.
15. Smith EM, Ritchie JM, Summersgill KF, et al: Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer 108: 766-772, 2004.
16. Carpagnano GE, Koutoulou A, Natalicchio MI, et al: HPV in exhaled breath condensate of lung cancer patients. Br J Cancer 105: 1183-1190, 2011.
17. van Boerdonck RA, Daniels JM, Bloemena E, et al: High-risk human papillomavirus-positive lung cancer: molecular evidence for a pattern of pulmonary metastasis. J Thorac Oncol 6: 711-718, 2013.